14 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 14 of 14 clinical reviews.
Tirzepatide is not FDA-approved for adolescent obesity. This evidence-based guide explains the current label, approved alternatives, and the limits of the available evidence.
A comprehensive clinical guide to Zepbound (tirzepatide) use in patients aged 65 and older, covering efficacy data, age-related physiologic changes, safety considerations, and dosing guidance from published trials and FDA labeling.
A clinical deep-dive into Zepbound (tirzepatide) use in patients aged 65 and older, covering efficacy data, safety considerations, dosing adjustments, muscle mass concerns, and how to weigh benefits against risks in older adults.
A clinical review of tirzepatide's potential developmental effects in children under 12, covering bone growth, puberty timing, neurological development, and why the drug remains unapproved for this age group.
Tirzepatide (Zepbound) is not FDA-approved for children under 12. This guide explains the current regulatory status, what limited pediatric data exist, and exactly how families should plan the transition from pediatric to adult obesity care.
Zepbound (tirzepatide) is not FDA-approved for children under 12. This evidence-based guide covers the clinical rationale, current trial data, safety concerns, and what physicians and families should know before considering off-label use in young children.
A clinician-grade guide to transitioning adolescents aged 12 to 17 from pediatric to adult obesity care while on Zepbound (tirzepatide), covering FDA approvals, dosing protocols, monitoring timelines, and practical handoff strategies.
Step-by-step caregiver guidance on administering Zepbound (tirzepatide) injections to adolescents ages 12 to 17, including dose escalation schedules, injection technique, storage, missed-dose rules, and safety monitoring.
A guide on how tirzepatide (Zepbound) affects school performance, physical activity, sports participation, and daily scheduling for adolescents ages 12 to 17.
Zepbound (tirzepatide) is not FDA-approved for children under 12. Learn what the current evidence shows, why off-label use carries serious risks in this age group, and what caregivers should know before any conversation with a pediatric specialist.
A complete clinical guide for caregivers helping adults aged 65 and older administer Zepbound (tirzepatide) injections safely, including dose preparation, injection technique, storage, side-effect monitoring, and when to call the prescriber.
A guide for adults 65 and older taking Zepbound (tirzepatide) covering safe physical activity, fall risk, muscle preservation, cognitive engagement, and community program guidance.
A comprehensive clinical review of tirzepatide (Zepbound) use in adolescents ages 12 to 17, covering growth, bone density, puberty, mental health, and current FDA approval status.
Tirzepatide (Zepbound) is not approved for children under 12. This guide covers what families, school nurses, and pediatricians need to know about GLP-1/GIP medications, physical activity, and school accommodations for young children with obesity.